Zola-cel trial results disclosed by Bristol Myers Squibb on October 23, 2026, included a patient death from septic pneumonia after treatment in an early-stage multiple sclerosis study. Shares fell 2% in midday trading that day. The company described the fatal event alongside preliminary efficacy findings, but its announcement did not establish that the investigational therapy caused the death.
Key Takeaways
- The patient died 44 days after infusion, following late-onset motor symptoms and treatment with several medicines.
- Bristol Myers reported no additional fatal adverse events among 190 patients treated in its Phase 1 autoimmune studies.
- Early efficacy findings came from a single-arm study designed primarily to assess safety, not a controlled comparison.
Table of Contents
- Zola-cel trial disclosure details the fatal event
- Early efficacy signals require longer follow-up
- Shares decline during the disclosure session
- Conclusion
Zola-cel trial disclosure details the fatal event
Bristol Myers’ Breakfree-2 interim results announcement said a patient with highly active relapsing multiple sclerosis experienced a fatal event of septic pneumonia after the study’s data cutoff. Zola-cel, formally named zolacabtagene autoleucel, is an investigational CD19-directed CAR T-cell therapy.
After infusion, the patient developed late-onset motor symptoms described as non-ICANS, distinguishing them from immune effector cell-associated neurotoxicity syndrome. Intermittent corticosteroids and intravenous immunoglobulin did not resolve those symptoms.
The company said the patient’s CAR T-cell expansion was consistent with observations across the study. High-dose cyclophosphamide was subsequently administered, and the patient developed septic pneumonia and died the following day, 44 days after infusion.
Bristol Myers reported no additional Grade 5, or fatal, adverse events across its zola-cel autoimmune programs, encompassing 190 patients treated in Phase 1 studies. That broader total is not the size of the multiple sclerosis cohort presented at the conference.
| Item | Details |
|---|---|
| Multiple sclerosis study population | 30 patients with highly active relapsing MS and 36 with progressive MS. |
| Previous treatment | Patients had received a median of two disease-modifying therapies. |
| Cytokine release syndrome | Reported in 28 of 66 patients; all events resolved in a median of two days. |
| ICANS | Reported in five of 66 patients; one Grade 4 event resolved within four days. |
Early efficacy signals require longer follow-up
The multiple sclerosis results presented at MSToronto 2026 covered 66 patients with ongoing disease activity or worsening disability despite previous treatment. Breakfree-2 is a single-arm, dose-escalation study with safety as its primary endpoint and efficacy as a secondary endpoint.
At the last follow-up, all 60 patients treated at dose level 2 remained off disease-modifying therapies, including nine with more than 12 months of follow-up. These observations preceded the subsequently disclosed fatal event.
Among evaluable patients with progressive multiple sclerosis, 22 of 24 showed stability or improvement in disability progression, and all 24 had no new MRI activity. These are preliminary findings from selected follow-up groups, rather than proof of benefit against a comparison treatment.
Shares decline during the disclosure session
Bristol Myers shares were down 2% in midday trading on October 23. That was an intraday move, not a closing result, and the timing alone does not establish how much of the decline was attributable to the clinical disclosure.
The development concerns an investigational treatment, not an approved multiple sclerosis product. The early efficacy observations and the fatal event therefore need to be assessed together as the company continues evaluating the treatment’s safety and potential benefits.
Conclusion
Further safety and efficacy follow-up in the ongoing Phase 1 program is the next substantive development to watch. The October 23 findings do not establish either a causal link between zola-cel and the death or a proven treatment benefit.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
